{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:44:34Z","timestamp":1789011874238,"version":"build-2803163510"},"reference-count":25,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T00:00:00Z","timestamp":1536105600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2019,1]]},"abstract":"Summary<\/jats:title>Spleen tyrosine kinase (Syk) mediates B\u2010cell receptor signalling in normal and malignant B cells. Entospletinib is an oral, selective Syk inhibitor. Entospletinib monotherapy was evaluated in a multicentre, phase 2 study of patients with relapsed or refractory indolent non\u2010Hodgkin lymphoma or mantle cell lymphoma (MCL<\/jats:styled-content>). Subjects received 800\u00a0mg entospletinib twice daily. Forty\u2010one follicular lymphoma (FL<\/jats:styled-content>), 17 lymphoplasmacytoid lymphoma\/Waldenstr\u00f6m macroglobulinaemia (LPL<\/jats:styled-content>\/WM<\/jats:styled-content>), 17 marginal zone lymphoma (MZL<\/jats:styled-content>) and 39 MCL<\/jats:styled-content> patients were evaluated. The primary endpoint was a progression\u2010free survival (PFS<\/jats:styled-content>) rate (defined as not experiencing progression or death) at 16\u00a0weeks for patients with MCL<\/jats:styled-content> and at 24\u00a0weeks for patients with FL<\/jats:styled-content>, LPL<\/jats:styled-content>\/WM<\/jats:styled-content> and MZL<\/jats:styled-content>. The most common treatment\u2010emergent adverse events were fatigue, nausea, diarrhoea, vomiting, headache and cough. Common laboratory abnormalities were anaemia, neutropenia and thrombocytopenia; aspartate transaminase, alanine transaminase, total bilirubin and serum creatinine were all increased. PFS<\/jats:styled-content> at 16\u00a0weeks in the MCL<\/jats:styled-content> cohort was 63\u00b79% [95% confidence interval (CI<\/jats:styled-content>) 45\u201377\u00b78%]; PFS<\/jats:styled-content> at 24\u00a0weeks in the FL<\/jats:styled-content>, LPL<\/jats:styled-content>\/WM<\/jats:styled-content>, MCL<\/jats:styled-content> and MZL<\/jats:styled-content> cohorts was 51\u00b75% (95% CI<\/jats:styled-content> 32\u00b78\u201367\u00b74%), 69\u00b78% (95% CI<\/jats:styled-content> 31\u00b78\u201389\u00b74%), 56\u00b76% (95% CI<\/jats:styled-content> 37\u00b75\u201371\u00b78%) and 46\u00b72% (95% CI<\/jats:styled-content> 18\u00b75\u201370\u00b72%), respectively. Entospletinib had limited single\u2010agent activity with manageable toxicity in these patient populations.<\/jats:p>","DOI":"10.1111\/bjh.15552","type":"journal-article","created":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T10:34:17Z","timestamp":1536143657000},"page":"215-222","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["An open\u2010label phase 2 trial of entospletinib in indolent non\u2010Hodgkin lymphoma and mantle cell lymphoma"],"prefix":"10.1111","volume":"184","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5699-4644","authenticated-orcid":false,"given":"David J.","family":"Andorsky","sequence":"first","affiliation":[{"name":"Rocky Mountain Cancer Centers\/The US Oncology Network Boulder CO USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn S.","family":"Kolibaba","sequence":"additional","affiliation":[{"name":"Compass Oncology\/The US Oncology Network Vancouver WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarit","family":"Assouline","sequence":"additional","affiliation":[{"name":"Gerald Bronfman Centre McGill University Montreal QC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Forero\u2010Torres","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham School of Medicine Birmingham AL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicky","family":"Jones","sequence":"additional","affiliation":[{"name":"North Star Lodge Cancer Center Yakima WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard M.","family":"Klein","sequence":"additional","affiliation":[{"name":"Illinois Cancer Specialists\/The US Oncology Network Niles IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipti","family":"Patel\u2010Donnelly","sequence":"additional","affiliation":[{"name":"Virginia Cancer Specialists\/The US Oncology Network Fairfax VA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1428-8765","authenticated-orcid":false,"given":"Mitchell","family":"Smith","sequence":"additional","affiliation":[{"name":"School of Medicine & Health Sciences The George Washington University Washington DC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Ye","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc. Foster City CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Shi","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc. Foster City CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher A.","family":"Yasenchak","sequence":"additional","affiliation":[{"name":"Willamette Valley Cancer Institute and Research Center\/The US Oncology Network Eugene OR USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff P.","family":"Sharman","sequence":"additional","affiliation":[{"name":"Willamette Valley Cancer Institute and Research Center\/The US Oncology Network Eugene OR USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,9,5]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.4084\/mjhid.2016.061"},{"key":"e_1_2_9_3_1","doi-asserted-by":"crossref","first-page":"5123","DOI":"10.1182\/blood.V126.23.5123.5123","article-title":"The combination of entospletinib and vincristine demonstrates synergistic activity in a broad panel of hematological cancer cell lines and anti\u2010tumor efficacy in a DLBCL xenograft model","volume":"126","author":"Axelrod M.J.","year":"2015","journal-title":"Blood"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-10-675009"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-233692"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.7534"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.21.120601.141018"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm500228a"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620717719616"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2013.1.553"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-236471"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.346"},{"key":"e_1_2_9_14_1","first-page":"S773","article-title":"The Dual SYK\/JAK inhibitor cerdulatinib demonstrates complete inhibition of SYK and JAK and rapid tumor responses in a phase 2 study in patients with relapsed\/refractory B Cell malignancies","volume":"102","author":"Hamlin P.","year":"2017","journal-title":"Haematologica"},{"key":"e_1_2_9_15_1","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1182\/blood.V128.22.624.624","article-title":"Updated results from a phase 1 study of TAK\u2010659, an investigational and reversible SYK inhibitor, in patients (Pts) with advanced solid tumor or lymphoma malignancies","volume":"128","author":"Kaplan J.B.","year":"2016","journal-title":"Blood"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2007.04.001"},{"key":"e_1_2_9_17_1","first-page":"2611","article-title":"Enhanced efficacy of the Syk inhibitor entospletinib and chemotherapy in infant acute lymphoblastic leukemia","volume":"130","author":"Loftus J.P.","year":"2017","journal-title":"Blood"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-212837"},{"key":"e_1_2_9_19_1","doi-asserted-by":"crossref","first-page":"Abstract","DOI":"10.1158\/1538-7445.AM2013-32","article-title":"Single and multiple dose\u2010ranging evaluation of safety, pharmacokinetics, and pharmacodynamics of GS\u20109973, a novel pSYK inhibitor","volume":"73","author":"Ramanathan S.","year":"2013","journal-title":"Cancer Research"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620716636542"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-08-595934"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw263"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4312"},{"key":"e_1_2_9_24_1","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow S.H.","year":"2008"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501548"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLML.2010.n.066"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.15552","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.15552","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.15552","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.15552","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T00:58:43Z","timestamp":1694393923000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.15552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,5]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["10.1111\/bjh.15552"],"URL":"https:\/\/doi.org\/10.1111\/bjh.15552","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,5]]},"assertion":[{"value":"2018-04-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-06-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-09-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}